Recombinantly Produced Neutral Protease Originating from Paenibacillus Polymyxa
Roche Diagnostics Operations, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 14/592,969, filed Jan 9, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,526,594 | Recombinantly Produced Neutral Protease Originating from Paenibacillus Polymyxa In force · Medium confidence | Roche Diagnostics Operations, Inc. | In force | Medium confidence | ||
| US 10,889,809 | Methods of Recombinantly Producing Neutral Protease Originating from Paenibacillus Polymyxa In force · Medium confidence | Roche Diagnostics Operations, Inc. | In force | Medium confidence | ||
| US 11,542,489 | An Expression Vector Encoding a Paenibacillus Polymxa Neutral Protease In force · Medium confidence | Roche Diagnostics Operations, Inc. | In force | Medium confidence | ||
| US 12,234,491 | Methods of Recombinantly Producing Neutral Protease Originating from Paenibacillus Polymxa In force · Medium confidence | Roche Diagnostics Operations, Inc. | In force | Medium confidence | ||
| Application 14/592,969 | Recombinantly Produced Neutral Protease Originating from Paenibacillus Polymyxa Abandoned Abandoned Nov 15, 2016 | Roche Diagnostics Operations, Inc. | Abandoned | Abandoned Nov 15, 2016 | ||
| Application 16/355,259 | Methods of Recombinantly Producing Neutral Protease Originating from Paenibacillus Polymyxa Abandoned Abandoned Nov 21, 2021 | Roche Diagnostics Operations, Inc. | Abandoned | Abandoned Nov 21, 2021 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Roche Diagnostics Operations, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.